Basit öğe kaydını göster

dc.contributor.authorCohen, P.
dc.contributor.authorBoguszewski, M.
dc.contributor.authorBurman, P.
dc.contributor.authorButler, G.
dc.contributor.authorChihara, K.
dc.contributor.authorChristiansen, J.
dc.contributor.authorClayton, P.
dc.contributor.authorClemmons, D.
dc.contributor.authorDeal, C.
dc.contributor.authorDunger, D.
dc.contributor.authorErfurth, E. M.
dc.contributor.authorFuqua, J. S.
dc.contributor.authorGrimberg, A.
dc.contributor.authorHaymond, M.
dc.contributor.authorHigham, C.
dc.contributor.authorHo, K.
dc.contributor.authorHoffman, A. R.
dc.contributor.authorHokken-Koelega, A.
dc.contributor.authorJohannsson, G.
dc.contributor.authorJuul, A.
dc.contributor.authorKopchick, J.
dc.contributor.authorLee, P.
dc.contributor.authorPollak, M.
dc.contributor.authorRadovick, S.
dc.contributor.authorRobison, L.
dc.contributor.authorRosenfeld, R.
dc.contributor.authorRoss, R. J.
dc.contributor.authorSavendahl, L.
dc.contributor.authorSaenger, P.
dc.contributor.authorSorensen, H. Toft
dc.contributor.authorStochholm, K.
dc.contributor.authorStrasburger, C.
dc.contributor.authorSwerdlow, A.
dc.contributor.authorThorner, M.
dc.contributor.authorDarendeliler, Fatma Feyza
dc.contributor.authorCianfarani, S.
dc.contributor.authorAllen, D. B.
dc.contributor.authorBackeljauw, P.
dc.contributor.authorBidlingmaier, M.
dc.contributor.authorBiller, B. M. K.
dc.date.accessioned2021-03-02T22:02:08Z
dc.date.available2021-03-02T22:02:08Z
dc.date.issued2016
dc.identifier.citationAllen D. B. , Backeljauw P., Bidlingmaier M., Biller B. M. K. , Boguszewski M., Burman P., Butler G., Chihara K., Christiansen J., Cianfarani S., et al., "GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults", EUROPEAN JOURNAL OF ENDOCRINOLOGY, cilt.174, sa.2, 2016
dc.identifier.issn0804-4643
dc.identifier.othervv_1032021
dc.identifier.otherav_0a53cd97-8436-4d73-a770-fc1f46517bf6
dc.identifier.urihttp://hdl.handle.net/20.500.12627/12695
dc.identifier.urihttps://doi.org/10.1530/eje-15-0873
dc.description.abstractRecombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.
dc.language.isoeng
dc.subjectKlinik Tıp
dc.subjectİç Hastalıkları
dc.subjectEndokrinoloji ve Metabolizma Hastalıkları
dc.subjectEndocrinology
dc.subjectEndocrine and Autonomic Systems
dc.subjectEndocrinology, Diabetes and Metabolism
dc.subjectLife Sciences
dc.subjectHealth Sciences
dc.subjectENDOKRİNOLOJİ VE METABOLİZMA
dc.subjectKlinik Tıp (MED)
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.titleGH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults
dc.typeMakale
dc.relation.journalEUROPEAN JOURNAL OF ENDOCRINOLOGY
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume174
dc.identifier.issue2
dc.contributor.firstauthorID230487


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster